HIGHBuilt-inProduct / Revenue mix
62%
MedSurg and Neurotechnology
“10-K Item 1: 'MedSurg and Neurotechnology | $15,647 | 62%'”
SYK · Concentration risk · 10-K extracted
Stryker (SYK) concentration risks
Updated
The most significant concentration Stryker discloses is MedSurg and Neurotechnology at 62%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Stryker’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
sole-source suppliers
“10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to...quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile combines a high-share product-segment focus and a high-share supplier dependency. On the product side, the MedSurg and Neurotechnology segment is disclosed with a revenue share; the source quote presents the figure in a pipe-delimited table format and is therefore described qualitatively: the MedSurg and Neurotechnology segment represents the largest disclosed portion of revenue, a high-share structural exposure reflecting the company's deliberate emphasis on medical devices and surgical products for hospital and ambulatory settings. This segment's performance is therefore the primary determinant of consolidated results, linking outcomes to surgical procedure volumes, capital equipment cycles, and hospital budget dynamics. On the supply side, several raw materials, components, finished devices, and services are procured from a sole source due to quality considerations, unique intellectual property considerations, or constraints associated with regulatory requirements, a high-share dependency. The dependency character is notable: sole-source arrangements in medical devices often arise not from commercial preference but from regulatory qualification requirements, meaning that switching to an alternative source requires a time-consuming revalidation process. A disruption at a sole-source supplier could therefore result in a prolonged production constraint rather than a quickly resolved logistical issue. The two exposures interact at the product level: the MedSurg and Neurotechnology segment — the company's largest — is the segment most likely to be affected by a sole-source supply disruption given its scale and complexity. No customer, geographic, or counterparty concentration is disclosed in the source claims. On balance, the concentrated product-segment focus and the sole-source supply dependencies are the two dimensions that warrant most attention in the disclosed concentration profile.
For the engine’s reasoning on SYK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| SYK● | Stryker Corporation | 2 | 0 | 0 | 2 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.